PRR5 Polyclonal Antibody, Invitrogen™
Manufacturer: Thermo Scientific
Select a Size
| Pack Size | SKU | Availability | Price |
|---|---|---|---|
| Each of 1 | PIPA521128-Each-of-1 | In Stock | ₹ 45,968.50 |
PIPA521128 - Each of 1
In Stock
Quantity
1
Base Price: ₹ 45,968.50
GST (18%): ₹ 8,274.33
Total Price: ₹ 54,242.83
Antigen
PRR5
Classification
Polyclonal
Conjugate
Unconjugated
Gene
PRR5
Gene Alias
Arhgap8; AU043908; C030017C09Rik; C78947; FLJ20185k; PP610; proline rich 5; proline rich 5 (renal); proline-rich protein 5; Protein observed with Rictor-1; Protor1; protor-1; prr5; prr5 {ECO:0000250; Rho GTPase activating protein 8; RP1-181C9.3; UniProtKB:P85299}
Host Species
Rabbit
Purification Method
Antigen affinity chromatography
Regulatory Status
RUO
Gene ID (Entrez)
109270, 315189, 55615
Content And Storage
Maintain refrigerated at 2-8°C for up to 3 months. For long term storage store at -20°C
Form
Liquid
Applications
Immunohistochemistry, Western Blot
Concentration
1 mg/mL
Formulation
PBS with 0.02% sodium azide
Gene Accession No.
P85299, Q5FVG6, Q812A5
Gene Symbols
PRR5
Immunogen
A 20 amino acid peptide near the carboxy terminus of human PRR5.
Quantity
100 μg
Primary or Secondary
Primary
Target Species
Human, Mouse, Rat
Product Type
Antibody
Isotype
IgG
Related Products
Description
- A suggested positive control is SK-N-SH cell lysate
- PA5-21128 can be used with blocking peptide PEP-1242
- MARK1 (MAP/microtubule affinity-regulating kinase 1) belongs to the MARK family of serine/threonine kinases
- MARK family protein kinases phosphorylate microtubule-associated proteins and may play a role in cytoskeletal stability
- MARK2 refers to MAP/microtubule affinity-regulating kinase 2 isoform a [Homo sapiens]
- EMK (ELKL Motif Kinase) is a small family of ser/thr protein kinases involved in the control of cell polarity, microtubule stability and cancer
- Several cDNA clones have been isolated that encoded two isoforms of the human ser/thr protein kinase EMK1 called MARK2
- MARK3 was originally identified as a marker that was induced by treatment with DNA damaging agents, and loss of MARK3 was found with carcinogenesis in the pancreas
- MARK4 contains an N terminal serine/threonine kinase domain, a central ubiquitin associated domain, and a C terminal KA1 associated kinase domain
- RT PCR analysis detects upregulated expression of the gene for MARK4 in nearly all clinical hepatocellular carcinoma cells.